258 related articles for article (PubMed ID: 26516228)
1. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Chretien ML; Corre J; Lauwers-Cances V; Magrangeas F; Cleynen A; Yon E; Hulin C; Leleu X; Orsini-Piocelle F; Blade JS; Sohn C; Karlin L; Delbrel X; Hebraud B; Roussel M; Marit G; Garderet L; Mohty M; Rodon P; Voillat L; Royer B; Jaccard A; Belhadj K; Fontan J; Caillot D; Stoppa AM; Attal M; Facon T; Moreau P; Minvielle S; Avet-Loiseau H
Blood; 2015 Dec; 126(25):2713-9. PubMed ID: 26516228
[TBL] [Abstract][Full Text] [Related]
2. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
3. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
5. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.
Kumar S; Fonseca R; Ketterling RP; Dispenzieri A; Lacy MQ; Gertz MA; Hayman SR; Buadi FK; Dingli D; Knudson RA; Greenberg A; Russell SJ; Zeldenrust SR; Lust JA; Kyle RA; Bergsagel L; Rajkumar SV
Blood; 2012 Mar; 119(9):2100-5. PubMed ID: 22234687
[TBL] [Abstract][Full Text] [Related]
6. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.
Sidana S; Jevremovic D; Ketterling RP; Tandon N; Dispenzieri A; Gertz MA; Greipp PT; Baughn LB; Buadi FK; Lacy MQ; Morice W; Hanson C; Timm M; Dingli D; Hayman SR; Gonsalves WI; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Rajkumar SV; Kumar SK
Am J Hematol; 2019 Apr; 94(4):424-430. PubMed ID: 30592078
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.
Mei J; Zhai Y; Li H; Li F; Zhou X; Song P; Zhao Q; Yu Y; An Z; Wang L
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2263-2273. PubMed ID: 30167888
[TBL] [Abstract][Full Text] [Related]
9. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
10. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Avet-Loiseau H; Attal M; Moreau P; Charbonnel C; Garban F; Hulin C; Leyvraz S; Michallet M; Yakoub-Agha I; Garderet L; Marit G; Michaux L; Voillat L; Renaud M; Grosbois B; Guillerm G; Benboubker L; Monconduit M; Thieblemont C; Casassus P; Caillot D; Stoppa AM; Sotto JJ; Wetterwald M; Dumontet C; Fuzibet JG; Azais I; Dorvaux V; Zandecki M; Bataille R; Minvielle S; Harousseau JL; Facon T; Mathiot C
Blood; 2007 Apr; 109(8):3489-95. PubMed ID: 17209057
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
12. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma.
Srour SA; Saliba RM; Bashir Q; Popat UR; Ahmed S; Mehta RS; Delgado R; Rondon G; Parmar S; Kebriaei P; Hosing C; Manasanch EE; Lee HC; Patel KK; Orlowski RZ; Shpall E; Champlin RE; Qazilbash MH; Nieto Y
Transplant Cell Ther; 2021 Mar; 27(3):243.e1-243.e6. PubMed ID: 33781521
[TBL] [Abstract][Full Text] [Related]
13. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.
Paul E; Sutlu T; Deneberg S; Alici E; Björkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Oncol Rep; 2009 Jul; 22(1):137-42. PubMed ID: 19513515
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.
Perrot A; Lauwers-Cances V; Tournay E; Hulin C; Chretien ML; Royer B; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Fontan J; Voillat L; Demarquette H; Collet P; Rodon P; Sohn C; Lifermann F; Orsini-Piocelle F; Richez V; Mohty M; Macro M; Minvielle S; Moreau P; Leleu X; Facon T; Attal M; Avet-Loiseau H; Corre J
J Clin Oncol; 2019 Jul; 37(19):1657-1665. PubMed ID: 31091136
[TBL] [Abstract][Full Text] [Related]
15. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
[TBL] [Abstract][Full Text] [Related]
17. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
Jacobson J; Barlogie B; Shaughnessy J; Drach J; Tricot G; Fassas A; Zangari M; Giroux D; Crowley J; Hough A; Sawyer J
Br J Haematol; 2003 Aug; 122(3):430-40. PubMed ID: 12877670
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
